RIGEL PHARMACEUTICALS INC
About RIGEL PHARMACEUTICALS INC
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $294.3M
- Net income
- $367.0M
- Total assets
- $513.6M
- Market cap
- $553.8M
- Gross margin
- 93.3%
- Operating margin
- 42.6%
- Net margin
- 124.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $294.3M
- Cost of revenue
- $19.6M
- Gross profit
- $274.7M
- Operating expenses
- $149.2M
- Operating income
- $125.5M
- Income tax
- -$245.2M
- Net income
- $367.0M
- EPS (basic)
- $20.40
- EPS (diluted)
- $19.48
Balance sheet
- Total assets
- $513.6M
- Current assets
- $240.2M
- Total liabilities
- $122.1M
- Current liabilities
- $99.2M
- Shareholders’ equity
- $391.5M
Cash flow
- Operating cash flow
- $75.7M
- Investing cash flow
- -$92.4M
- Financing cash flow
- $601.0K
- Net cash flow
- -$16.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $553.8M
- P/E ratio
- 1.5
- EPS (diluted)
- $19.48
- Shares outstanding
- 18.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 29, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $367.0M in FY2025.
- Revenue grew 97% from FY2021 to FY2025.
- Gross margin of 93.3%, net margin 124.7%.
- Trading 41% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RIGEL PHARMACEUTICALS INC.
Write a review
News about RIGEL PHARMACEUTICALS INC
News & sentiment via Polygon.io
